What Moved on the CY2026 ASC Covered-Procedures List, and What It Does to Your Facility Fee
The short version for busy ASC operators: a large batch of cases that used to be blocked at your door in 2025 can finally be paid in the surgery center in 2026. The money question is not whether a code was added. It is which payment indicator it landed on.
Before 2025 → After CY2026
The site-of-service hurdle, line by line
Same procedure, same patient. What changed is the status your claim carries into the ASC. Read the two middle columns as a swap: a blocking status on the left, an active surgical payment indicator on the right. The far-right column is the part your CFO cares about.
Families and representative code ranges illustrate the payment-indicator mechanics. Confirm every specific CPT against CY2026 ASC Addendum AA and Addendum BB, and against your commercial and Medicare Advantage plan policies, before you bill. The Medicare IPO removals do not force outpatient. A case can still be done inpatient when the physician documents the need.
Why J8 is the check you want
The device-intensive offset, in four moves
This is the single policy that decides whether an implant case is worth doing in your ASC. Follow the device dollars.
Measure the device share
CMS compares the implant cost to the full ASC procedure rate for that code.
Cross the 30% line
When the device is at least 30% of the ASC rate, the code earns device-intensive status.
Payment indicator J8 attaches
The device portion is packaged and protected rather than scaled down by the ASC conversion.
ASC rate = HOPD rate
Your facility fee is set to the hospital outpatient amount, so the implant does not sink the case.
Read the indicator, not the headline
Three ways a CY2026 addition hits your fee
A code being added to the CPL is only step one. The payment indicator tells you whether the addition is real revenue, a thin margin, or a trap.
Real new volume
Paid at the ASC rate. Good for lower-acuity additions where your cost to deliver sits under the rate. Model the case cost before you schedule it.
The margin protector
Rate set to the HOPD amount because the implant is packaged at cost. This is where high-device cases finally pencil out in the ASC instead of the hospital.
The quiet trap
Medicare adds the code, but a commercial or Medicare Advantage plan still calls it inpatient. Fix the contract and the prior-auth rule, or the addition never lands.
Field guide
The three statuses that decide the money
The 2025 blocker. Medicare would not pay the case in an ASC. The CY2026 rule begins clearing this over three years.
Non office-based surgical procedure added to the ASC list. Paid at the standard ASC rate. The most common landing spot for new additions.
Device-intensive procedure. Rate set to the hospital outpatient rate so the packaged device is not underpaid. The high-value additions live here.
Do this before January
Turn the rule into collected dollars
The additions are worth nothing until your chargemaster, contracts, and auth rules catch up. A short, concrete list:
Match every code you perform against ASC Addendum AA and BB. Flag each new G2 and J8.
Set charges above the new rate for added codes, and confirm device-intensive lines carry the implant.
Medicare adding a code does not bind commercial or Medicare Advantage. Check each plan medical policy.
New ASC codes often still need auth. Update your worklists so scheduling does not book an uncovered case.
The cases that shifted are mostly musculoskeletal. Make sure the OR block plan reflects what can now move.
Track first-pass denials on the new codes for 90 days and route the site-of-service denials fast.
The guidelines behind every number on this page
- CMS CY2026 OPPS/ASC Final Rule (Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System, released November 21, 2025). Source for the 2.6% ASC update, the additions to the Covered Procedures List, and the Inpatient Only list phase-out.
- ASC Covered Procedures List, 42 CFR 416.166. The inclusion and general-standards framework CMS used to add the CY2026 procedures, including the revised exclusion criteria now framed as physician safety considerations.
- Device-intensive procedure offset policy. The 30% device-cost threshold and the rule that a device-intensive (J8) procedure is paid at the hospital outpatient rate, with the offset computed on ASC rates since CY2022.
- CY2026 ASC Addendum AA and Addendum BB. The authoritative code-level list of covered procedures and their payment indicators. Always the final check before you bill.
- CY2026 ASC payment update methodology. The hospital market basket of 3.3%, netted against the 0.7% productivity adjustment, that produced the 2.6% ASC update.
Know exactly which CY2026 codes pay in your ASC
ASP-RCM Solutions maps the new Covered Procedures List against your case mix, your payer contracts, and your chargemaster, so every added code lands with the right indicator and gets paid the first time. Our ASC billing team runs the addenda so your schedulers do not have to.
Get your CY2026 ASC fee reviewRelated reading
Onboarding the CY2026 ASC Covered Procedures List, one dated step at a time
A dated onboarding timeline for adding CY2026 ASC Covered Procedures List additions to the chargemaster and ap
Read →InsightThe rule in five numbers
CMS-1850-P proposes a 2.4% CY2027 payment update for OPPS and ASC while cutting 340B-acquired drugs to ASP min
Read →Field noteThe second line is where ASC money quietly leaks.
How the ASC 50% multiple-procedure reduction and modifiers 50, 51, 59, 73, and 74 change the actual paid amoun
Read →